Targeting the Plasma High Density Lipoprotein Receptor (SR-B1) for Effective Anti-Cancer Therapeutics

StatusFinished
Effective start/end date1/03/16 → 1/03/17

Funding

  • LipoMedics, Ltd. Co.: $63,431.00
View all
View less

Keywords

  • Biotechnology & Drug Development, Cancer Research, Nanotechnology